EP3938535A1 - Detection of double stranded nucleic acids in situ and methods related thereto - Google Patents
Detection of double stranded nucleic acids in situ and methods related theretoInfo
- Publication number
- EP3938535A1 EP3938535A1 EP20770887.6A EP20770887A EP3938535A1 EP 3938535 A1 EP3938535 A1 EP 3938535A1 EP 20770887 A EP20770887 A EP 20770887A EP 3938535 A1 EP3938535 A1 EP 3938535A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- target
- amplifiers
- amplifier
- sample
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 414
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 409
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 409
- 238000000034 method Methods 0.000 title claims abstract description 108
- 238000001514 detection method Methods 0.000 title claims description 82
- 238000011065 in-situ storage Methods 0.000 title description 20
- 239000000523 sample Substances 0.000 claims description 996
- 238000009739 binding Methods 0.000 claims description 403
- 210000004369 blood Anatomy 0.000 claims description 68
- 239000008280 blood Substances 0.000 claims description 68
- 230000002380 cytological effect Effects 0.000 claims description 62
- 238000009396 hybridization Methods 0.000 claims description 58
- 230000008018 melting Effects 0.000 claims description 33
- 238000002844 melting Methods 0.000 claims description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000012296 in situ hybridization assay Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 96
- 108020004414 DNA Proteins 0.000 description 95
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 72
- 210000001519 tissue Anatomy 0.000 description 69
- 238000003556 assay Methods 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 27
- -1 DNA Chemical class 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- 238000007901 in situ hybridization Methods 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000003321 amplification Effects 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 102000053602 DNA Human genes 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 102000040430 polynucleotide Human genes 0.000 description 17
- 108091033319 polynucleotide Proteins 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 239000007850 fluorescent dye Substances 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 13
- 238000013461 design Methods 0.000 description 11
- 239000003593 chromogenic compound Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 7
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 238000003508 chemical denaturation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 239000002679 microRNA Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 108020004418 ribosomal RNA Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 238000011895 specific detection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 3
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 3
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002787 antisense oligonuctleotide Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108091064355 mitochondrial RNA Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052761 rare earth metal Inorganic materials 0.000 description 3
- 150000002910 rare earth metals Chemical class 0.000 description 3
- 238000011896 sensitive detection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108090000316 Pitrilysin Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- WIXAQXKQLNRFDF-UHFFFAOYSA-N n-[4-[7-(diethylamino)-4-methyl-2-oxochromen-3-yl]phenyl]-2-iodoacetamide Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C1=CC=C(NC(=O)CI)C=C1 WIXAQXKQLNRFDF-UHFFFAOYSA-N 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 150000003220 pyrenes Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- QEQDLKUMPUDNPG-UHFFFAOYSA-N 2-(7-amino-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(N)C=CC2=C1OC(=O)C(CC(O)=O)=C2C QEQDLKUMPUDNPG-UHFFFAOYSA-N 0.000 description 1
- BNBQQYFXBLBYJK-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-oxazole Chemical class C1=COC(C=2N=CC=CC=2)=N1 BNBQQYFXBLBYJK-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- KYVGMGQCZKBVDT-OWVAZHOYSA-N 3-acetyl-7-beta-D-glucopyranosyloxycoumarin Chemical compound C1=C2OC(=O)C(C(=O)C)=CC2=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYVGMGQCZKBVDT-OWVAZHOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- CXNVOWPRHWWCQR-UHFFFAOYSA-N 4-Chloro-ortho-toluidine Chemical compound CC1=CC(Cl)=CC=C1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-CHUNWDLHSA-N 4-methylumbelliferyl alpha-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-CHUNWDLHSA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- WNDDWSAHNYBXKY-UHFFFAOYSA-N ATTO 425-2 Chemical compound CC1CC(C)(C)N(CCCC(O)=O)C2=C1C=C1C=C(C(=O)OCC)C(=O)OC1=C2 WNDDWSAHNYBXKY-UHFFFAOYSA-N 0.000 description 1
- YIXZUOWWYKISPQ-UHFFFAOYSA-N ATTO 565 para-isomer Chemical compound [O-]Cl(=O)(=O)=O.C=12C=C3CCC[N+](CC)=C3C=C2OC=2C=C3N(CC)CCCC3=CC=2C=1C1=CC(C(O)=O)=CC=C1C(O)=O YIXZUOWWYKISPQ-UHFFFAOYSA-N 0.000 description 1
- PWZJEXGKUHVUFP-UHFFFAOYSA-N ATTO 590 meta-isomer Chemical compound [O-]Cl(=O)(=O)=O.C1=2C=C3C(C)=CC(C)(C)N(CC)C3=CC=2OC2=CC3=[N+](CC)C(C)(C)C=C(C)C3=CC2=C1C1=CC=C(C(O)=O)C=C1C(O)=O PWZJEXGKUHVUFP-UHFFFAOYSA-N 0.000 description 1
- SLQQGEVQWLDVDF-UHFFFAOYSA-N ATTO 610-2 Chemical compound [O-]Cl(=O)(=O)=O.C1=C2CCC[N+](CCCC(O)=O)=C2C=C2C1=CC1=CC=C(N(C)C)C=C1C2(C)C SLQQGEVQWLDVDF-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108050001427 Avidin/streptavidin Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- HIHVCASFAJDRKI-UHFFFAOYSA-N C1=CC=C2C(O)=C(Cl)C=CC2=C1.C1=CC=C2C(O)=CCC(Cl)(C#N)C2=C1 Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1.C1=CC=C2C(O)=CCC(Cl)(C#N)C2=C1 HIHVCASFAJDRKI-UHFFFAOYSA-N 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 230000003350 DNA copy number gain Effects 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- IXQIUDNVFVTQLJ-UHFFFAOYSA-N Naphthofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=C2C=CC2=CC(O)=CC=C21 IXQIUDNVFVTQLJ-UHFFFAOYSA-N 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- FOYVTVSSAMSORJ-UHFFFAOYSA-N atto 655 Chemical compound OC(=O)CCCN1C(C)(C)CC(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 FOYVTVSSAMSORJ-UHFFFAOYSA-N 0.000 description 1
- MHHMNDJIDRZZNT-UHFFFAOYSA-N atto 680 Chemical compound OC(=O)CCCN1C(C)(C)C=C(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 MHHMNDJIDRZZNT-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000008191 permeabilizing agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
Definitions
- the present invention relates generally to detection of nucleic acids, and more specifically to detection of double stranded nucleic acids in situ.
- ISH DNA in situ hybridization
- the invention provides methods of detecting a double stranded nucleic acid.
- the invention provides a method of detecting a double stranded nucleic acid comprising (A) contacting a sample comprising a cell comprising one or more double stranded nucleic acids with a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid; (B) contacting the sample with a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier; (C) contacting the sample with a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe; (D)
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or derived from a cytological sample.
- the inventions provides a sample of fixed and permeabilized cells, comprising (A) at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier, wherein the pre-amplifier is hybridized to the first and second target probes; (D) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe, and wherein the amplifiers are hybridized to the pre-amplifier; and (E
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or derived from a cytological sample.
- the invention provides a slide comprising (A) a slide having immobilized thereon a plurality of fixed and permeabilized cells comprising at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier, wherein the pre-amplifier is hybridized to the first and second target probes; (D) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe, and wherein the amplifiers are
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA
- RNA or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or derived from a cytological sample.
- the invention provides a kit for detection of a target double stranded nucleic acid, comprising (A) a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier; (B) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe; and (C) a plurality of label probes, wherein the label probe comprises a label and a binding site for the amplifiers.
- the kit comprises a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the kit comprises at least one reagent for permeabilizing cells.
- the invention provides a method of detecting a double stranded nucleic acid comprising (A) contacting a sample comprising a cell comprising one or more double stranded nucleic acids with a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid; (B) contacting the sample with a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre- pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre- amplifier comprises a binding site for the second target probe, and wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier; (C) contacting the sample with a plurality
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both pre-pre-amplifiers is higher than the melting temperature between the binding of only one pre-pre-amplifier.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a sample of fixed and permeabilized cells, comprising (A) at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre-pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre-amplifier comprises a binding site for the second target probe, wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier, and wherein the pre-pre-amplifiers are hybridized to the first and second target probes; (A) at least one fixed and
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both pre-pre-amplifiers is higher than the melting temperature between the binding of only one pre-pre-amplifier.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a slide comprising (A) a slide having immobilized thereon a plurality of fixed and permeabilized cells comprising at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre- pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre- amplifier comprises a binding site for the second target probe, and wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier, and wherein the pre-pre-amplifiers
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both regions is higher than the melting temperature between the binding of only one region.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA
- RNA or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a kit for detection of a target double stranded nucleic acid, comprising (A) a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre-pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre-amplifier comprises a binding site for the second target probe, and wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier; (B) a plurality of pre-amplifiers, wherein the pre amplifiers comprise a binding site for the first and second pre-pre-amplifiers and a plurality of binding sites for an amplifier; (C) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifiers and a plurality of binding sites for a label probe; and (D) a plurality of label probes, wherein the label probe comprises a label and a binding site for
- the kit comprises a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both regions is higher than the melting temperature between the binding of only one region.
- the kit comprises at least one reagent for permeabilizing cells.
- the invention provides a method of detecting a double stranded nucleic acid comprising: (A) contacting a sample comprising a cell comprising one or more double stranded nucleic acids with a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid; (B) contacting the sample with a pre- pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier; (C) contacting the sample with a plurality of pre-amplifiers comprising a binding site for the pre-pre-amplifier, and a plurality of binding sites for an amplifier; (D) contacting the sample with a plurality of amplifiers,
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a sample of fixed and permeabilized cells, comprising: (A) at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier, wherein the pre-pre-amplifier is hybridized to the first and second target probes; (D) a plurality of pre-amplifiers comprising a binding site for the pre-pre-amplifiers and a plurality of binding sites for an amplifier, wherein the pre-amplifiers are hybridized to the
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a slide comprising (A) a slide having immobilized thereon a plurality of fixed and permeabilized cells comprising at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier, wherein the pre-pre- amplifier is hybridized to the first and second target probes; (D) a plurality of pre-amplifiers comprising a binding site for the pre-pre-amplifier and a plurality of binding sites for an amplifier, wherein
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA
- RNA or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a kit for detection of a target double stranded nucleic acid, comprising (A) a pre-pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier; (B) a pre-amplifier comprising a binding site for the pre-pre-amplifier and a plurality of binding sites for an amplifier; (C) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe; and (D) a plurality of label probes, wherein the label probe comprises a label and a binding site for the amplifiers.
- the kit comprises a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the target double stranded nucleic acid.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the kit comprises at least one reagent for permeabilizing cells.
- Figure 1 shows a schematic of probe designs (double strand probes (ds-probes)) for detecting double stranded DNA, RNA or DNA/RNA hybrid. For each probe pair
- the target-binding region of one probe binds to the sense strand whereas that of the other probe binds to the anti-sense strand of double stranded DNA, RNA or DNA-RNA hybrid. Simultaneous binding of each probe of the pair forms a binding site for the pre-amplifier (Panels A and B). Panels A and B show two alternative exemplary probe orientations. Panel C shows adaption of the same probe design for the BaseScopeTM signal amplification system (Baker et al., Nat. Commun. 8(1): 1998, doi: 10.1038/s41467-017-02295- 5 (2017)).
- Panel C depicts binding of each member of the pair of target probes to the sense and antisense strands of the target nucleic acid, respectively.
- Each target probe binds to a separate pre-pre-amplifier (Panel C).
- one or more probe pairs can be designed to target the same double stranded nucleic acid.
- Figure 2 shows a flow diagram for the steps for an exemplary in situ hybridization assay (left), and a modified assay using chemical denaturation (right) to denature double stranded nucleic acids.
- the standard protocol starts with baking a slide at 60°C followed by deparaffmization to remove the paraffin wax (“Bake+Dewax”).
- the slide is then treated with Epitope Retrieval buffer (“ER2”) at 88°C to unmask the target(s), followed by protease digestion (Protease III).
- ER2 Epitope Retrieval buffer
- target probes are hybridized to the slide (“Probe”), which is followed by sequential hybridization with pre-amplifiers, amplifiers and label probes (“AMPs”) and then detection of the target with the chromogen Fast Red (“Detection”).
- Detection The modified protocol for DNA detection adds a chemical denaturation step (“Chemical DN”,
- Figure 3 shows detection of fibroblast growth factor receptor 1 (FGFR1) genomic DNA detection requires both Z1 (sense strand binding) and Z2 (antisense strand binding) probes, which ensures specificity for double stranded DNA. DNA was detected as red punctate dots inside nuclei (blue).
- FGFR1 fibroblast growth factor receptor 1
- Figure 4 shows detection of different genes in cells (HEK293) and tissues (colon cancer, ovarian cancer, normal pancreas, normal breast) by ds-probes. DNA was detected as red punctate dots inside nuclei (blue).
- Figures 5A-5C show a schematic of previously described methods of detecting a nucleic acid target using a signal generating complex (SGC).
- SGC signal generating complex
- the methods provide for highly sensitive and specific detection of double stranded nucleic acids in a cell.
- RNAscopeTM uses specially designed oligonucleotide probes, sometimes referred to as "double-Z" or ZZ probes, in combination with a branched-DNA-like signal amplification system to reliably detect RNA as small as 1 kilobase at single-molecule sensitivity under standard bright-field microscopy (Anderson et ah, J Cell. Biochem. 117(10):2201-2208 (2016); Wang et ah, ./. Mol. Diagn. 14(l):22-29 (2012)).
- Such a probe design greatly improves the specificity of signal amplification because only when both probes in each pair bind to their intended target can signal amplification occur.
- RNAscopeTM for DNA detection is hampered by unwanted RNA detection because RNAscopeTM probes cannot discriminate DNA from RNA targets.
- RNA can be eliminated by enzymatic (for example, RNase A) and chemical (for example, NaOH) methods, adding these steps can cause significant degradation of nuclear and cellular morphology and compromise DNA detection or detection of double stranded nucleic acids in an in situ detection assay.
- RNAscopeTM RNAscopeTM signal amplification system without interference from RNA. This is achieved by designing each probe pair to bind to both strands of double stranded nucleic acid, such as double stranded DNA, RNA or DNA/RNA hybrid. Single stranded RNA or DNA will not be detected because only one of the two probes in each pair will bind to it, which effectively prevents signal amplification and detection of single stranded RNA and single stranded DNA targets.
- the assay strategy allows highly sensitive and specific detection of very short DNA sequences (as short as lkb), providing a ⁇ 100-fold higher resolution than current DNA FISH assays.
- the methods of the invention selectively detect double stranded DNA, which make it possible to distinguish double stranded DNA from single stranded DNA.
- the methods of the invention are also applicable to distinguishing double stranded RNA and/or RNA-DNA hybrid from single stranded DNA and/or RNA.
- this method preserves RNA when detecting DNA, the methods can be used for simultaneous detection of RNA and DNA targets in the same sample of cells or tissue section.
- the present invention relates to methods that allow for highly sensitive and specific detection of nucleic acid sequences in a cell, in particular double stranded nucleic acids.
- the methods of the invention have numerous practical applications (Hu et al., supra , 2014; Ratan et al., supra , 2017; Weier et al., supra , 2002).
- the methods of the invention can be used, for example, in physical mapping of DNA sequences in chromosomes; three dimensional (3D) mapping of spatial genome organization; detection of gene copy number gain (duplication and amplification), loss (deletion) and gene rearrangement (translocation and fusion) in diseased cells and tissues; prenatal, postnatal and pre-transplantation diagnosis of chromosomal abnormalities; cancer diagnosis and prognosis; companion diagnostics; and detection and identification of pathogens (for example, bacteria and viruses).
- the present invention extends the probe design principle at the core of the
- RNAscopeTM technology Wang et al., supra , 2012 to double stranded nucleic acid, such as DNA, detection by requiring each probe pair to bind both strands of a double stranded nucleic acid, such as DNA, for signal amplification to occur ( Figure 1).
- each probe contains a sequence segment that binds to a specific sequence in the target.
- double stranded nucleic acid detection for example, DNA detection
- two probes bind to adjacent sites on opposite strands in the target double stranded nucleic acid.
- the target probe“Z is depicted in a“Z” configuration, as described, for example, in U.S. Patent No. 7,709,198, U.S. publications 2008/0038725 and
- the Zi configuration shown in Figure 1 has the target binding site 5' to the pre-amplifier or pre-pre-amplifier binding site of the target probe ( Figures 1 A-1C). It is understood that such a configuration, as depicted in Figure 1, is merely exemplary, and the orientation can be the reverse, that is, the target binding site can be 3' to the pre-amplifier or pre-pre-amplifier binding site.
- probe“Z2” is depicted with the pre-amplifier binding site 5' to the target binding site.
- the probe“Z2” depicts the target binding site 5' to the pre amplifier binding site.
- the“Z2” probe is similarly depicted with the target binding site 5' to the pre-pre-amplifier binding site.
- the target probe pair can independently be in either orientation, that is, one member of the pair of target probes can have the target binding site 5' or 3' to the pre-amplifier or pre-pre-amplifier binding site, and can be paired with a second probe having a binding site 5' or 3' to the pre-amplifier or pre- pre-amplifier, such that there are four possible combinations of orientations for the target probe pairs.
- the two strands are labeled as“sense” and“antisense” for the purposes of illustration. It is understood that the target probe pairs bind to opposite strands of a double stranded nucleic acid. It is further understood that the region of a double stranded nucleic acid to be bound by the target probe pair does not need to be in a coding region, for example, a coding region of DNA having sense and antisense strands, but can be in a non coding region.
- HCR v3.0 HCR v3.0
- RNAscopeTM Choi et al., supra , 2018
- This technique can use similarly designed probe pairs binding to both DNA strands, as described herein, in order to initiate the hybridization chain reaction, which will ensure dsDNA specificity.
- Multiplexing to detect multiple double stranded nucleic acid targets, for example, multiple DNA targets, simultaneously on the same slide is straightforward with the use of either RNAscopeTM or BaseScopeTM technology.
- the methods of the invention disclosed herein can be used to detect any double stranded nucleic acid, such as DNA biomarkers, in various cells and tissue types.
- the ds-probe design is used with RNAscopeTM to detect multiple gene targets in cells and tissues (see Example 1 and Figure 4).
- the methods of the invention can be used to detect and characterize a variety of DNA structural variations such as deletion, insertion, gene fusion, translocation, duplication, and amplification found in neoplasms and other diseases.
- the methods of the invention can also be used to detect double stranded viral DNA and RNA and bacterial DNA with double-strand specificity.
- label probe refers to an entity that binds to a target molecule, directly or indirectly, generally indirectly, and allows the target to be detected.
- a label probe (or "LP") contains a nucleic acid binding portion that is typically a single stranded polynucleotide or oligonucleotide that comprises one or more labels which directly or indirectly provides a detectable signal.
- the label can be covalently attached to the
- the polynucleotide or the polynucleotide can be configured to bind to the label.
- a biotinylated polynucleotide can bind a streptavi din-associated label.
- the label probe can, for example, hybridize directly to a target nucleic acid.
- the label probe can hybridize to a nucleic acid that is in turn hybridized to the target nucleic acid or to one or more other nucleic acids that are hybridized to the target nucleic acid.
- the label probe can comprise a polynucleotide sequence that is complementary to a polynucleotide sequence, particularly a portion, of the target nucleic acid.
- the label probe can comprise at least one polynucleotide sequence that is complementary to a polynucleotide sequence in an amplifier, pre-amplifier, pre-pre-amplifier, signal generating complex (SGC), or the like, as described herein.
- the label probe binds to an amplifier.
- a label probe comprising an enzyme label refers to a label probe comprising a nucleic acid binding portion such as an oligonucleotide and an enzyme that is coupled to the nucleic acid binding portion.
- the coupling of the enzyme to the nucleic acid binding portion can be covalent or through a high affinity binding interaction such as biotin/avidin or other similar high affinity binding molecules.
- a "target probe” is a polynucleotide that is capable of hybridizing to a target nucleic acid and capturing or binding a label probe or signal generating complex (SGC) component, for example, an amplifier, pre-amplifier or pre-pre-amplifier, to that target nucleic acid.
- SGC signal generating complex
- the target probe can hybridize directly to the label probe, or it can hybridize to one or more nucleic acids that in turn hybridize to the label probe; for example, the target probe can hybridize to an amplifier, a pre-amplifier or a pre-pre-amplifier in an SGC.
- the target probe thus includes a first polynucleotide sequence that is complementary to a polynucleotide sequence of the target nucleic acid and a second polynucleotide sequence that is complementary to a polynucleotide sequence of the label probe, amplifier, pre-amplifier, pre-pre-amplifier, or the like.
- the target probe binds to a pre-amplifier, as in Figures 1 A and IB, or to a pre-pre-amplifier, as in Figure 1C.
- the target probe is generally single stranded so that the complementary sequence is available to hybridize with a corresponding target nucleic acid, label probe, amplifier, pre-amplifier or pre-pre-amplifier.
- the target probes are provided as a pair, wherein one member of the pair binds to one strand of the double stranded nucleic acid, and the other target probe binds to the opposite strand of the double stranded nucleic acid.
- an "amplifier” is a molecule, typically a polynucleotide, that is capable of hybridizing to multiple label probes. Typically, the amplifier hybridizes to multiple identical label probes. The amplifier can also hybridize to a target nucleic acid, to at least one target probe of a pair of target probes, to both target probes of a pair of target probes, or to nucleic acid bound to a target probe such as an amplifier, pre-amplifier or pre-pre- amplifier. For example, the amplifier can hybridize to at least one target probe and to a plurality of label probes, or to a pre-amplifier and a plurality of label probes.
- the amplifier can hybridize to a pre-amplifier.
- the amplifier can be, for example, a linear, forked, comb-like, or branched nucleic acid.
- the amplifier can include modified nucleotides and/or nonstandard internucleotide linkages as well as standard deoxyribonucleotides,
- Suitable amplifiers are described, for example, in U.S. Patent Nos. 5,635,352, 5,124,246, 5,710,264, 5,849,481, and 7,709,198 and U.S.
- the amplifier binds to a pre-amplifier and label probes (see Figure 5).
- a "pre-amplifier” is a molecule, typically a polynucleotide, that serves as an intermediate binding component between one or more target probes and one or more amplifiers. Typically, the pre-amplifier hybridizes simultaneously to one or more target probes and to a plurality of amplifiers. Exemplary pre-amplifiers are described, for example, in U.S. Patent Nos. 5,635,352, 5,681,697 and 7,709,198 and U.S. publications 2008/0038725, 2009/0081688 and 2017/0101672, each of which is incorporated by reference.
- a pre-amplifier binds to both members of a target probe pair (see Figure 1 A, IB and 5A), to a pre-pre-amplifier that can bind to a target probe pair ( Figure 5B), or to both members of a pair of pre-pre-amplifiers that can bind to a target probe pair (see Figure 5C).
- a pre-amplifier also binds to an amplifier (see Figure 5).
- a "pre-pre-amplifier” is a molecule, typically a polynucleotide, that serves as an intermediate binding component between one or more target probes and one or more pre-amplifiers. Typically, the pre-pre-amplifier hybridizes simultaneously to one or more target probes and to a plurality of pre-amplifiers. Exemplary pre-pre-amplifiers are described, for example, in 2017/0101672, which is incorporated by reference.
- a pre-pre-amplifier binds to a target probe pair (see Figure 5B) or to a member of a target probe pair (see Figures 1C and 5C) and to a pre-amplifier (see Figure 5C).
- a plurality can refer to, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more, 40 or more, 41 or more, 42 or more, 43 or more, 44 or more, 45 or more, 46 or more, 47 or more, 48 or more, 49 or more, 50 or more, 55 or more, 60 or more, 65 or more, 70 or more, 75 or more, 80 or
- the invention provides a method of detecting a double stranded nucleic acid comprising: (A) contacting a sample comprising a cell comprising one or more double stranded nucleic acids with a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid; (B) contacting the sample with a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier; (C) contacting the sample with a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe; (D) contacting the sample with a plurality of label probes, wherein the label probe
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a method of detecting a double stranded nucleic acid comprising (A) contacting a sample comprising a cell comprising one or more double stranded nucleic acids with a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid; (B) contacting the sample with a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre- pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre- amplifier comprises a binding site for the second target probe, and wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier; (C) contacting the sample with a plurality
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both pre- pre-amplifiers is higher than the melting temperature between the binding of only one pre-pre- amplifier.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a method of detecting a double stranded nucleic acid comprising (A) contacting a sample comprising a cell comprising one or more double stranded nucleic acids with a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid; (B) contacting the sample with a pre- pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier; (C) contacting the sample with a plurality of pre-amplifiers comprising a binding site for the pre-pre-amplifier, and a plurality of binding sites for an amplifier; (D) contacting the sample with a plurality of amplifiers, where
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- each target probe set that is specific for a target nucleic acid comprises two or more pairs of target probes that specifically hybridize to the same target double stranded nucleic acid.
- the pairs of target probes in the target probe set specific for a target nucleic acid bind to different and non-overlapping sequences of the target nucleic acid.
- the molecule that binds to the target probe pairs either a pre-amplifier (see Figures 1 A, IB and 5 A), or a pre-pre-amplifier (see Figures 1C, 5B and 5C), generally are the same for target probe pairs in the same target probe set.
- the target probe pairs that bind to the same target double stranded nucleic acid can be designed to comprise the same binding site for the molecule in the SGC that binds to the target probe pairs, that is, a pre-amplifier or pre-pre- amplifier.
- the use of multiple target probe pairs to detect a target nucleic acid provides for a higher signal associated with the assembly of multiple SGCs on the same target nucleic acid.
- the number of target probe pairs used for binding to the same target nucleic acid are in the range of 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-80, 1-90, 1-100, 1- 110, 1-120, 1-130, 1-140, 1-150, 1-160, 1-170, 1-180, 1-190, or 1-200 pairs per target, or larger numbers of pairs, or any integer number of pairs in between, for example, 1, 2, 3, 4, 5,
- a target nucleic acid is detected with a plurality of target probe pairs.
- target probe pairs are designed to bind to more than one region of a target nucleic acid to allow for the assembly of multiple SGCs onto a target nucleic acid. It is understood that the target binding sites of one target probe pair do not overlap with the target binding sites of another target probe pair if a plurality of target probe pairs are being used to bind to the same target nucleic acid.
- the target nucleic acids detected by the methods of the invention can be any double stranded target nucleic acid present in the cell sample.
- the target nucleic acids can independently be DNA, double stranded RNA or DNA/RNA hybrids.
- the target nucleic acids to be detected can be, but are not necessarily, the same type of nucleic acid.
- the methods of the invention can be combined with methods for detecting single stranded nucleic acids, such as RNAscopeTM or BaseScopeTM, such that both double stranded and single stranded nucleic acids can be detected in the same sample.
- the target nucleic acids include but not limited to, RNA, including messenger RNA (mRNA), micro RNA (miRNA), ribosomal RNA (rRNA), mitochondrial RNA, non-coding RNA, and the like, or DNA, and the like, or DNA/RNA hybrids.
- RNA messenger RNA
- miRNA messenger RNA
- miRNA micro RNA
- rRNA ribosomal RNA
- mitochondrial RNA non-coding RNA
- DNA and the like, or DNA/RNA hybrids.
- the target nucleic acids can independently be selected from the group consisting of messenger RNA (mRNA), micro RNA (miRNA), ribosomal RNA (rRNA), mitochondrial RNA, and non coding RNA.
- the target nucleic acids can independently be DNA, either single stranded or double stranded, or any type of RNA, either signal stranded or double stranded, or
- the methods of the invention generally relate to in situ detection of double stranded nucleic acids.
- Methods for in situ detection of nucleic acids are well known to those skilled in the art (see, for example, US 2008/0038725; US
- ISH in situ hybridization
- the probe types can be double stranded DNA (dsDNA), single stranded DNA (ssDNA), single stranded complimentary RNA (sscRNA), messenger RNA (mRNA), micro RNA (miRNA), ribosomal RNA, mitochondrial RNA, and/or synthetic oligonucleotides.
- dsDNA double stranded DNA
- ssDNA single stranded DNA
- sscRNA single stranded complimentary RNA
- mRNA messenger RNA
- miRNA micro RNA
- ribosomal RNA mitochondrial RNA
- synthetic oligonucleotides synthetic oligonucleotides.
- FISH fluorescent in situ hybridization
- CISH chromogenic in situ hybridization
- ISH, FISH and CISH methods are well known to those skilled in the art (see, for example, Stoler, Clinics in Laboratory Medicine 10(1):215-236 (1990); In situ hybridization. A practical approach , Wilkinson, ed., IRL Press, Oxford (1992); Schwarzacher and Heslop-Harrison, Practical in situ hybridization , BIOS Scientific Publishers Ltd, Oxford (2000)).
- the cell is optionally fixed and/or permeabilized before hybridization of the target probes. Fixing and
- permeabilizing cells can facilitate retaining the nucleic acid targets in the cell and permit the target probes, label probes, amplifiers, pre-amplifiers, pre-pre-amplifiers, and so forth, to enter the cell and reach the target nucleic acid molecule.
- the cell is optionally washed to remove materials not captured to a nucleic acid target.
- the cell can be washed after any of various steps, for example, after hybridization of the target probes to the nucleic acid targets to remove unbound target probes, after hybridization of the pre-pre-amplifiers, pre-amplifiers, amplifiers, and/or label probes to the target probes, and the like.
- Exemplary fixing agents include, but are not limited to, aldehydes (formaldehyde, glutaraldehyde, and the like), acetone, alcohols (methanol, ethanol, and the like).
- Exemplary permeabilizing agents include, but are not limited to, alcohols (methanol, ethanol, and the like), acids (glacial acetic acid, and the like), detergents (Triton, NP-40, TweenTM 20, and the like), saponin, digitonin, LeucopermTM (BioRad, Hercules, CA), and enzymes (for example, lysozyme, lipases, proteases and peptidases). Permeabilization can also occur by mechanical disruption, such as in tissue slices.
- the sample is treated to denature the double stranded nucleic acids in the sample to provide accessibility for the target probes to bind by hybridization to both strands of the target double stranded nucleic acid.
- Conditions for denaturing double stranded nucleic acids are well known in the art, and include heat and chemical denaturation, for example, with base (NaOH), formamide, dimethyl sulfoxide, and the like (see Wang et ak, Environ. Health Toxicol. 29:e2014007 (doi:
- FIG. 2 An exemplary assay protocol is outlined in Figure 2.
- the assay depicted in Figure 2 corresponds to the RNAScopeTM 2.5 LS Red assay (user manual 322150, Advanced Cell Diagnostics, Newark CA) for use on a Leica Biosystems BOND RX system (Leica
- Biosystems, Buffalo Grove, IL Briefly, the standard protocol starts with baking a slide at 60°C and followed by deparaffmization to remove the paraffin wax (“Bake+Dewax”). The slide is then treated with Epitope Retrieval buffer (“ER2”) at 88°C to unmask the target(s), followed by protease digestion (Protease III). Then, target probes are hybridized to the slide (“Probe”), which is followed by sequential hybridization with pre-amplifiers, amplifiers and label probes (“AMPs”) and then detection of the target with the chromogen Fast Red.
- ER2 Epitope Retrieval buffer
- AMPs pre-amplifiers, amplifiers and label probes
- the modified protocol for DNA detection adds a chemical denaturation step (“Chemical DN”, 70% formamide in 2XSSC at 80°C for 20 minutes).
- tissue specimens immobilized on a glass slide on single cells in suspension such as peripheral blood mononucleated cells (PBMCs) isolated from blood samples, and the like.
- Tissue specimens include, for example, tissue biopsy samples.
- Blood samples include, for example, blood samples taken for diagnostic purposes.
- the blood can be directly analyzed, such as in a blood smear, or the blood can be processed, for example, lysis of red blood cells, isolation of PBMCs or leukocytes, isolation of target cells, and the like, such that the cells in the sample analyzed by methods of the invention are in a blood sample or are derived from a blood sample.
- tissue specimen can be processed, for example, the tissue specimen minced and treated physically or enzymatically to disrupt the tissue into individual cells or cell clusters.
- a cytological sample can be processed to isolate cells or disrupt cell clusters, if desired.
- the tissue, blood and cytological samples can be obtained and processed using methods well known in the art.
- the methods of the invention can be used in diagnostic applications to identify the presence or absence of pathological cells based on the presence or absence of a double stranded nucleic acid target that is a biomarker indicative of a pathology.
- the sample for use in methods of the invention will generally be a biological sample or tissue sample.
- a biological sample can be obtained from a biological subject, including a sample of biological tissue or fluid origin that is collected from an individual or some other source of biological material such as biopsy, autopsy or forensic materials.
- a biological sample also includes samples from a region of a biological subject containing or suspected of containing precancerous or cancer cells or tissues, for example, a tissue biopsy, including fine needle aspirates, blood sample, or cytological specimen.
- Such samples can be, but are not limited to, organs, tissues, tissue fractions and/or cells isolated from an organism such as a mammal.
- Exemplary biological samples include, but are not limited to, a cell culture, including a primary cell culture, a cell line, a tissue, an organ, an organelle, a biological fluid, and the like.
- Additional biological samples include but are not limited to a skin sample, tissue biopsies, including fine needle aspirates, cytological samples, stool, bodily fluids, including blood and/or serum samples, saliva, semen, and the like. Such samples can be used for medical or veterinary diagnostic purposes.
- a sample can also be obtained from other sources, for example, food, soil, surfaces of objects, and the like, and other materials for which detection of double stranded nucleic acids is desired.
- the methods of the invention can be used for detection of one or more pathogens, such as a double stranded DNA or RNA virus, a bacterium, a fungus, a single celled organism, such as a parasite, and the like, from a biological sample obtained from an individual or other sources.
- the cytological sample is a cervical sample, for example, a pap smear. In one embodiment, the sample is a fine needle aspirate.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention is based on building a complex between a target double stranded nucleic acid in order to label the double stranded nucleic acid with a detectable label.
- a complex is sometimes referred to as a signal generating complex (SGC; see, for example, US 20170101672).
- SGC signal generating complex
- Such a complex, or SGC is achieved by building layers of molecules that allow the attachment of a large number of labels to a target double stranded nucleic acid.
- the methods of the invention can employ a signal generating complex (SGC), where the SGC comprises multiple molecules rather than a single molecule.
- SGC signal generating complex
- Such an SGC is particularly useful for amplifying the detectable signal, providing higher sensitivity detection of target nucleic acids.
- Such methods for amplifying a signal are described, for example, in U.S. Patent Nos. 5,635,352, 5,124,246, 5,710,264, 5,849,481, and 7,709,198, and U.S.
- FIG. 5A A basic Signal Generating Complex (SGC) is illustrated in Figure 5A (see also US 2009/0081688, which is incorporated herein by reference).
- SGC Signal Generating Complex
- Figure 5A A pair of target probes, depicted in Figure 5 as a pair of "Z's", hybridizes to a complementary molecule sequence, labeled "Target”.
- Figure 5 depicts the target as a single line, whereas it is understood that the target in the present invention is a double stranded nucleic acid, as illustrated in Figure 1 in more detail.
- Each target probe contains an additional sequence complementary to a pre-amplifier molecule (PA, illustrated in green), which must hybridize simultaneously to both members of the target probe pair in order to bind stably.
- the pre-amplifier molecule is made up of two domains: one domain with a region that hybridizes to each target probe, and one domain that contains a series of nucleotide sequence repeats, each complementary to a sequence on the amplifier molecule (Amp, illustrated in black). The presence of multiple repeats of this sequence allows multiple amplifier molecules to hybridize to one pre-amplifier, which increases the overall signal amplification.
- Each amplifier molecule is made up of two domains, one domain with a region that hybridizes to the pre-amplifier, and one domain that contains a series of nucleotide sequence repeats, each complementary to a sequence on the label probe (LP, illustrated in yellow), allowing multiple label probes to hybridize to each amplifier molecule, further increasing the total signal amplification.
- Each label probe contains two components. One component is made up of a nucleotide sequence
- the label probe is depicted as a line, representing the nucleic acid component, and a star, representing the signal-generating component. Together, the assembly from target probe to label probe is referred to as a Signal Generating Complex (SGC).
- SGC Signal Generating Complex
- Figure 5B illustrates a SGC enlarged by adding an amplification molecule layer, in this case a pre-pre-amplifier molecule (PPA, shown in red).
- PPA pre-pre-amplifier molecule
- the PPA binds to both target probes in one domain and multiple pre-amplifiers (PAs) in another domain.
- Figure 5C illustrates a different SGC structure that uses collaborative hybridization at the pre-amplifier level (see US 2017/0101672, which is incorporated herein by reference).
- a pair of target probes hybridize to the target molecule sequence.
- Each target probe contains an additional sequence complementary to a unique pre-pre-amplifier molecule (PPA-1, illustrated in purple; PPA-2, illustrated in red).
- PPA-1 illustrated in purple
- PPA-2 illustrated in red
- Each pre-pre-amplifier molecule is made up of two domains, one domain with a region that hybridizes to one of the target probes, and one domain that contains a series of nucleotide sequence repeats, each containing both a sequence
- each PA must hybridize to both PPA molecules simultaneously.
- Each pre amplifier molecule is made up of two domains, one domain that contains sequences complementary to both pre-pre-amplifiers to allow hybridization, and one domain that contains a series of nucleotide sequence repeats each complementary to a sequence on the amplifier molecule (AMP, illustrated in black). Multiple repeats of the amplifier
- hybridization sequence allows multiple amplifier molecules to hybridize to each pre amplifier, further increasing signal amplification.
- amplifier molecules are shown hybridizing to one pre-amplifier molecule, but it is understood that amplifiers can bind to each pre-amplifier.
- Each amplifier molecule contains a series of nucleotide sequence repeats complementary to a sequence within the label probe (LP, illustrated in yellow), allowing several label probes to hybridize to each amplifier molecule.
- Each label probe contains a signal -generating element to provide for signal detection.
- Tm melting temperature
- This design has been described previously, for example, in U.S. Patent No. 7,709,198, U.S. publications 2008/0038725 and 2009/0081688, WO 2007/001986 WO 2007/002006, Wang et al., supra , 2012, Anderson et al., supra , 2016).
- the requirement that an SGC be formed only when both members of a target probe pair are bound to the target nucleic acid is achieved by requiring that a pre-amplifier be bound to both pre-pre-amplifiers, which in turn are bound to both members of the target probe pair, respectively.
- This requirement is achieved by designing the binding sites between the pre-pre-amplifiers and the pre-amplifier such that the melting temperature (Tm) between the binding of both pre-pre-amplifiers to the pre-amplifier is higher than the melting temperature of either pre-pre-amplifier alone, and where the binding of one of the pre-pre-amplifiers to the pre-amplifier is unstable under the conditions of the assay.
- the invention is based on building a signal-generating complex (SGC) bound to a target nucleic acid in order to detect the presence of the target nucleic acid in the cell.
- the components for building an SGC generally comprise nucleic acids such that nucleic acid hybridization reactions are used to bind the components of the SGC to the target nucleic acid.
- oligonucleotides or probes that specifically and selectively bind to a target nucleic acid, or other components of the SGC are well known to those skilled in the art (see Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999)).
- the target probes are designed such that the probes specifically hybridize to a target nucleic acid.
- a desired specificity can be achieved using appropriate selection of regions of a target nucleic acid as well as appropriate lengths of a binding agent such as an oligonucleotide or probe, and such selection methods are well known to those skilled in the art.
- reagents such as oligonucleotides or probes
- target nucleic acid over another target nucleic acid or over non-target nucleic acids, or to provide binding to the components of the SGC.
- “specifically hybridize,”“specifically label,” and“specifically bind” refer to hybridization, labeling or binding to a target nucleic acid but not to non-target nucleic acids, for example, another target nucleic acid or nucleic acids that are not desired to be targeted.
- Similar specificity can be achieved for a target-specific SGC by using appropriate selection of unique sequences such that a given component of a target-specific SGC (for example, target probe, pre-pre-amplifier, pre-amplifier, amplifier, label probe) will bind to the respective components such that the target-specific SGC is bound to a specific target and not to another target nucleic acid.
- a given component of a target-specific SGC for example, target probe, pre-pre-amplifier, pre-amplifier, amplifier, label probe
- embodiments of the invention include the use of target probe pairs, with each member of the pair binding to opposite strands of a double stranded nucleic acid.
- a pair of target probes binds to the same pre-amplifier ( Figures 1 A,
- a probe configuration sometimes referred to as a“Z” configuration, can be used.
- a“Z” configuration Such a configuration and its advantages for increasing sensitivity and decreasing background are described, for example, in U.S. Patent No.
- 7,709,198 and U.S. publications 2008/0038725 and 2009/0081688 additionally describe details for selecting characteristics of the target probes, such as target probe pairs, including length, orientation, hybridization conditions, and the like.
- One skilled in the art can readily identify suitable configurations based on the teachings herein and, for example, in U.S. Patent No. 7,709,198, U.S. publications 2008/0038725 and 2009/0081688, and WO 2007/001986 and WO 2007/002006.
- the target binding site of the target probes in a target probe pair can be in any desired orientation and combination.
- the target binding site of one member of the target probe pair can be 5' or 3' to the pre-amplifier or pre-pre-amplifier binding site, and the other member of the pair can independently be oriented with the target binding site 5' or 3' to the pre-amplifier or pre-pre-amplifier binding site.
- the SGC used to detect the presence of a target double stranded nucleic acid is based on a collaborative hybridization of one or more components of the SGC (see US 20170101672 and WO 2017/066211, each of which is incorporated herein by reference).
- a collaborative hybridization is also referred to herein as BaseScopeTM
- a collaborative hybridization effect the binding between two components of an SGC is mediated by two binding sites, and the melting temperature of the binding to the two sites simultaneously is higher than the melting temperature of the binding of one site alone (see US 20170101672 and WO 2017/066211).
- the collaborative hybridization effect can be enhanced by target probe set configurations as described in US 20170101672 and WO 2017/066211.
- the methods of the invention, and related compositions can utilize collaborative hybridization to increase specificity and to reduce background in in situ detection of double stranded nucleic acid targets, where a complex physiochemical environment and the presence of an overwhelming number of non-target molecules can generate high noise.
- a collaborative hybridization method the binding of label probes only occurs when the SGC is bound to the target nucleic acid.
- the method can be readily modified to provide a desired signal to noise ratio by increasing the number of collaborative hybridizations in one or more components of the SGC.
- the collaborative hybridization can be applied to various components of the SGC.
- the binding between components of an SGC can be a stable reaction, as described herein, or the binding can be configured to require a collaborative hybridization, also as described herein.
- the binding component intended for collaborative hybridization are designed such that the component contains two segments that bind to another component.
- the methods for detecting a target nucleic acid can utilize collaborative hybridization for the binding reactions between any one or all of the components in the detection system that provides an SGC specifically bound to a target nucleic acid.
- the number of components, and which components, to apply collaborative hybridization can be selected based on the desired assay conditions, the type of sample being assayed, a desired assay sensitivity, and so forth. Any one or combination of collaborative hybridization binding reactions can be used to increase the sensitivity and specificity of the assay.
- the collaborative hybridization can be between a pre-pre-amplifier and a pre amplifier, between a pre-amplifier and an amplifier, between an amplifier and a label probe, or combinations thereof (see, for example, US 20170101672 and WO 2017/066211).
- the components are generally bound directly to each other.
- the binding reaction is generally by hybridization.
- the binding between the components is direct.
- an intermediary component can be included such that the binding of one component to another is indirect , for example, the intermediary component contains complementary binding sites to bridge two other components.
- the configuration of various components can be selected to provide a desired stable or collaborative hybridization binding reaction (see, for example, US 20170101672). It is understood that, even if a binding reaction is exemplified herein as a stable or unstable reaction, such as for a collaborative hybridization, any of the binding reactions can be modified, as desired, so long as the target double stranded nucleic acid is detected. It is further understood that the configuration can be varied and selected depending on the assay and hybridization conditions to be used.
- the segments of complementary nucleic acid sequence between the components is generally in the range of 10 to 50 nucleotides, or greater, for example, 16 to 30 nucleotides, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides, or greater.
- the segments of complementary nucleic acid sequence between the components is generally in the range of 5 to 18 nucleotides, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 nucleotides. It is understood that the nucleotide lengths can be somewhat shorter or longer for a stable or unstable hybridization, depending on the sequence (for example, GC content) and the conditions employed in the assay. It is further understood, as disclosed herein, that modified nucleotides such as Locked Nucleic Acid (LNA) or Bridged Nucleic Acid (BNA) can be used to increase the binding strength at the modified base, thereby allowing length of the binding segment to be reduced.
- LNA Locked Nucleic Acid
- BNA Bridged Nucleic Acid
- nucleic acid segments that are complementary to other nucleic acid segments can be reduced further, if desired.
- a person skilled in the art can readily determine appropriate probe designs, including length, the presence of modified nucleotides, and the like, to achieve a desired interaction between nucleic acid components.
- the complementary sequences can optionally be designed to maximize the difference in melting temperature (dT m ). This can be done by using melting temperature calculation algorithms known in the art (see, for example, SantaLucia, Proc. Natl. Acad. Sci. U.S.A. 95: 1460-1465 (1998)).
- artificial modified bases such as Locked Nucleic Acid (LNA) or bridged nucleic acid (BNA) and naturally occurring 2'-0- methyl RNA are known to enhance the binding strength between complementary pairs (Petersen and Wengel, Trends Biotechnol. 21 :74-81 (2003); Majlessi et ah, Nucl. Acids Res. 26:2224-2229 (1998)).
- LNA Locked Nucleic Acid
- BNA bridged nucleic acid
- 2'-0- methyl RNA naturally occurring 2'-0- methyl RNA
- One approach is to utilize modified nucleotides (LNA, BNA or 2'-0-methyl RNA). Because each modified base can increase the melting temperature, the length of binding regions between two nucleic acid sequences (i.e., complementary sequences) can be substantially shortened. The binding strength of a modified base to its complement is stronger, and the difference in melting temperatures (dT m ) is increased. Yet another embodiment is to use three modified bases (for example, three LNA, BNA or 2'-0-methyl RNA bases, or a combination of two or three different modified bases) in the complementary sequences of a nucleic acid component or between two nucleic acid components, for example of a signal generating complex (SGC), that are to be hybridized. Such components can be, for example, pre-pre-amplifier, a pre-amplifier, an amplifier, a label probe, or a pair of target probes.
- SGC signal generating complex
- the modified bases such as LNA or BNA
- LNA or BNA can be used in the segments of selected components of SGC, in particular those mediating binding between nucleic acid components, which increases the binding strength of the base to its complementary base, allowing a reduction in the length of the complementary segments (see, for example, Petersen and Wengel, Trends Biotechnol. 21 :74-81 (2003); US Patent No. 7,399,845).
- Artificial bases that expand the natural 4-letter alphabet such as the Artificially Expanded Genetic Information System (AEGIS; Yang et al., Nucl. Acids Res. 34 (21): 6095-6101 (2006)) can be used.
- AEGIS Artificially Expanded Genetic Information System
- the target probe pair can be designed to bind to immediately adjacent segments of the target nucleic acid or on segments that have one to a number of bases between the target probe binding sites of the target probe pair.
- target probe pairs are designed for binding to the target nucleic acid such that there are generally between 0 to 500 bases between the binding sites on the target nucleic acid, for example, 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, or 500 bases, or any integer length in between.
- the binding sites for the pair of target probes are between 0 and 100, for example, 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or any integer length in between.
- the members of the target probe pair bind to opposite strands of the double stranded nucleic acid (see, for example, Figure 1).
- the binding sites of the pair of target probes are on opposite strands.
- the target binding sites for the pair of probes can overlap since the binding sites occur on opposite strands for the respective members of the target probe pair. It is understood that overlap can occur so long as there is no steric hindrance for the simultaneous binding of both target probes to the respective target nucleic acid strands. A person skilled in the art can readily determine permissible overlap between target binding sites on opposite strands, if such overlap is desired.
- the SGC also comprises a plurality of label probes (LPs).
- Each LP comprises a segment that is detectable.
- the detectable component can be directly attached to the LP, or the LP can hybridize to another nucleic acid that comprises the detectable component, i.e. the label.
- a "label" is a moiety that facilitates detection of a molecule. Common labels in the context of the present invention include fluorescent, luminescent, light-scattering, and/or colorimetric labels.
- Suitable labels include enzymes, and fluorescent and chromogenic moieties, as well as radionuclides, substrates, cofactors, inhibitors, chemiluminescent moieties, magnetic particles, rare earth metals, metal isotopes, and the like.
- the label is an enzyme.
- Exemplary enzyme labels include, but are not limited to Horse Radish Peroxidase (HRP), Alkaline Phosphatase (AP), b- galactosidase, glucose oxidase, and the like, as well as various proteases.
- Other labels include, but are not limited to, fluorophores, Dinitrophenyl (DNP), and the like.
- Labels are well known to those skilled in the art, as described, for example, in Hermanson, Bioconjugate Techniques , Academic Press, San Diego (1996), and U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
- Many labels are commercially available and can be used in methods and assays of the invention, including detectable enzyme/substrate combinations (Pierce, Rockford IL; Santa Cruz Biotechnology, Dallas TX; Life Technologies, Carlsbad CA).
- the enzyme can utilize a chromogenic or fluorogenic substrate to produce a detectable signal, as described herein. Exemplary labels are described herein.
- any of a number of enzymes or non-enzyme labels can be utilized so long as the enzymatic activity or non-enzyme label, respectively, can be detected.
- the enzyme thereby produces a detectable signal, which can be utilized to detect a target nucleic acid.
- Particularly useful detectable signals are chromogenic or fluorogenic signals.
- particularly useful enzymes for use as a label include those for which a chromogenic or fluorogenic substrate is available. Such chromogenic or fluorogenic substrates can be converted by enzymatic reaction to a readily detectable chromogenic or fluorescent product, which can be readily detected and/or quantified using microscopy or spectroscopy.
- Such enzymes are well known to those skilled in the art, including but not limited to, horseradish peroxidase, alkaline phosphatase, b-galactosidase, glucose oxidase, and the like (see Hermanson, Bioconjugate Techniques , Academic Press, San Diego (1996)).
- Other enzymes that have well known chromogenic or fluorogenic substrates include various peptidases, where chromogenic or fluorogenic peptide substrates can be utilized to detect proteolytic cleavage reactions.
- chromogenic and fluorogenic substrates are also well known in bacterial diagnostics, including but not limited to the use of a- and b-galactosidase, b-glucuronidase, 6-phospho ⁇ - D-galatoside 6-phosphogalactohydrolase, b-gluosidase, a-glucosidase, amylase,
- chromogenic or fluorogenic substrates to produce detectable signals are well known to those skilled in the art and are commercially available.
- Exemplary substrates that can be utilized to produce a detectable signal include, but are not limited to, 3,3'- diaminobenzidine (DAB), 3,3’,5,5’-tetramethylbenzidine (TMB), Chloronaphthol (4-CN)(4- chloro-l-naphthol), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), o- phenylenediamine dihydrochloride (OPD), and 3-amino-9-ethylcarbazole (AEC) for horseradish peroxidase; 5-bromo-4-chloro-3-indolyl-l-phosphate (BCIP), nitroblue tetrazolium (NBT), Fast Red (Fast Red TR/AS-MX), and p
- fluorogenic substrates include, but are not limited to, 4-(Trifluoromethyl)umbelliferyl phosphate for alkaline phosphatase; 4-Methylumbelliferyl phosphate bis (2-amino- 2-methyl- 1,3 -propanediol), 4-Methylumbelliferyl phosphate bis (cyclohexylammonium) and 4- Methylumbelliferyl phosphate for phosphatases; QuantaBluTM and QuantaRedTM for horseradish peroxidase; 4-Methylumbelliferyl b-D-galactopyranoside, Fluorescein di ⁇ -D- galactopyranoside) and Naphthofluorescein di- ⁇ -D-galactopyranoside) for b-galactosidase; 3-Acetylumbelliferyl b-D-glucopyranoside and 4-Methyl umbel 1 iferyl -b- D-glucopyranoside for b
- Exemplary enzymes and substrates for producing a detectable signal are also described, for example, in US publication 2012/0100540.
- Various detectable enzyme substrates including chromogenic or fluorogenic substrates, are well known and commercially available (Pierce, Rockford IL; Santa Cruz Biotechnology, Dallas TX; Invitrogen, Carlsbad CA; 42 Life Science; Biocare).
- the substrates are converted to products that form precipitates that are deposited at the site of the target nucleic acid.
- exemplary substrates include, but are not limited to, HRP-Green (42 Life Science), Betazoid DAB, Cardassian DAB, Romulin AEC, Bajoran Purple, Vina Green, Deep Space BlackTM, Warp RedTM, Vulcan Fast Red and Ferangi Blue from Biocare (Concord CA;
- Exemplary rare earth metals and metal isotopes suitable as a detectable label include, but are not limited to, lanthanide (III) isotopes such as 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, and 176Yb.
- III lanthanide
- Metal isotopes can be detected, for example, using time-of-flight mass spectrometry (TOF-MS) (for example, Fluidigm Helios and Hyperion systems, fluidigm.com/systems; South San Francisco, CA).
- TOF-MS time-of-flight mass spectrometry
- Biotin-avidin (or biotin-streptavidin) is a well known signal amplification system based on the fact that the two molecules have extraordinarily high affinity to each other and that one avidin/streptavidin molecule can bind four biotin molecules.
- Antibodies are widely used for signal amplification in immunohistochemistry and ISH. Tyramide signal
- TSA tyrene-se
- Tyramine is a phenolic compound.
- HRP immobilized Horse Radish Peroxidase
- the activated substrate molecules then very rapidly react with and covalently bind to electron-rich moieties of proteins, such as tyrosine, at or near the site of the peroxidase binding site.
- proteins such as tyrosine
- Embodiments described herein can utilize enzymes to generate a detectable signal using appropriate chromogenic or fluorogenic substrates. It is understood that, alternatively, a label probe can have a detectable label directly coupled to the nucleic acid portion of the label probe. Exemplary detectable labels are well known to those skilled in the art, including but not limited to chromogenic or fluorescent labels (see Hermanson, Bioconjugate Techniques , Academic Press, San Diego (1996)).
- fluorophores useful as labels include, but are not limited to, rhodamine derivatives, for example, tetramethylrhodamine, rhodamine B, rhodamine 6G, sulforhodamine B, Texas Red (sulforhodamine 101), rhodamine 110, and derivatives thereof such as tetramethylrhodamine-5-(or 6), lissamine rhodamine B, and the like; 7-nitrobenz-2-oxa-l, 3-diazole (NBD); fluorescein and derivatives thereof; napthalenes such as dansyl (5-dimethylaminonapthalene-l-sulfonyl); coumarin derivatives such as 7- amino-4-methylcoumarin-3 -acetic acid (AMCA), 7-diethylamino-3-[(4'- (iodoacetyl)amino)phenyl]-4-methylcoumarin (DCIA),
- the methods of the invention can utilize concurrent detection of multiple target nucleic acids.
- fluorophores as labels
- the fluorophores to be used for detection of multiple target nucleic acids are selected so that each of the fluorophores are distinguishable and can be detected concurrently in the fluorescence microscope in the case of concurrent detection of target nucleic acids.
- fluorophores are selected to have spectral separation of the emissions so that distinct labeling of the target nucleic acids can be detected concurrently.
- cytometry e.g., mass cytometry, cytometry by time of flight (CyTOF), flow cytometry
- spectroscopy can be utilized to visualize chromogenic, fluorescent, or metal detectable signals associated with the respective target nucleic acids.
- cytometry e.g., mass cytometry, cytometry by time of flight (CyTOF), flow cytometry
- spectroscopy can be utilized to visualize chromogenic, fluorescent, or metal detectable signals associated with the respective target nucleic acids.
- chromogenic substrates or fluorogenic substrates, or chromogenic or fluorescent labels, or rare earth metal isotopes will be utilized for a particular assay, if different labels are used in the same assay, so that a single type of instrument can be used for detection of nucleic acid targets in the same sample.
- the methods of the invention can be utilized to achieve the detection of desired target double stranded nucleic acids.
- a target nucleic acid is detected with a plurality of target probe pairs.
- target probe pairs are designed to bind to more than one region of a target double stranded nucleic acid. It is understood that the target binding sites of one target probe pair do not overlap with the target binding sites of another target probe pair if a plurality of target probe pairs are being used to bind to the same target double stranded nucleic acid.
- the methods of the invention can be applied to multiplex detection of target double stranded nucleic acids.
- the methods of the invention are applied to the detection of two or more target nucleic acids, for example, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more target nucleic acids.
- the number of target nucleic acids that can be detected depends on the detection label. For fluorescent labels, up to 10 nucleic targets can generally be detected. For metal tagged probes using mass spectrometry-based detection, the number of target nucleic acids can be up to 150.
- a person skilled in the art can readily select suitable distinct labels to allow detection of more than one target double stranded nucleic acid in a sample.
- the methods of the invention can be applied to simultaneous detection of double stranded nucleic acids and single stranded nucleic acids, for example, detection of DNA and RNA in the same sample.
- probes can be designed to detect single stranded nucleic acids, such as RNA (see, for example, U.S. Patent No. 7,709,198, U.S. publications 2008/0038725 and 2009/0081688, and 2017/0101672) and double stranded nucleic acids, as described herein, such that both double stranded nucleic acids and single stranded nucleic acids, such as DNA and RNA, can be detected in the same sample.
- the invention described herein generally relates to detection of double stranded nucleic acids in a sample. It is understood that the methods of the invention can additionally be applied to detecting target nucleic acids and optionally other molecules in the sample, in particular in the same cell as the target nucleic acid.
- proteins expressed in a cell can also concurrently be detected. Detection of proteins in a cell are well known to those skilled in the art, for example, by detecting the binding of protein-specific antibodies using any of the well known detection systems, including those described herein for detection of target nucleic acids. Detection of target nucleic acids and protein have been described (see, for example, Schulz et ah, Cell Syst. 6(l):25-36 (2016)).
- the invention can be carried out in any desired order, so long as the double stranded target nucleic acid is detected.
- the steps of contacting a cell with any components for assembly of an SGC can be performed in any desired order, can be carried out sequentially, or can be carried out simultaneously, or some steps can be performed sequentially while others are performed simultaneously, as desired, so long as the target double stranded nucleic acid is detected.
- embodiments disclosed herein can be independently combined with other embodiments disclosed herein, as desired, in order to utilize various configurations, component sizes, assay conditions, assay sensitivity, and the like.
- the number of assay steps it can be desirable to reduce the number of assay steps, for example, reduce the number of hybridization and wash steps.
- One way of reducing the number of assay steps is to pre-assemble some or all components of the SGC prior to contacting with a cell. Such a pre-assembly can be performed by hybridizing some or all of the components of the SGC together prior to contacting the target nucleic acid.
- the invention can be carried out in any format that provides for the detection of a target nucleic acid. Although implementation of the invention has generally been described herein using in situ hybridization, it is understood that the invention can be carried out for detection of target nucleic acids in other formats, in particular for detection of target nucleic acids in a cell, as are well known in the art.
- One method that can be used for detecting target nucleic acids in a cell is flow cytometry, as is well known in the art (see, for example, Shapiro, Practical Flow Cytometry 3rd ed., Wiley-Liss, New York (1995); Ormerod, Flow Cytometry , 2nd ed., Springer (1999)).
- the methods, samples and kits of the invention can thus be used in an in situ hybridization assay format or another format, such as flow cytometry.
- an in situ hybridization assay format or another format, such as flow cytometry.
- nucleic acid detection methods, including in situ hybridization, to flow cytometry has been described previously (see, for example, Hanley et ah, PLoS One, 8(2):e57002. doi: 10.1371/journal. pone.0057002 (2013); Baxter et ah, Nature Protocols 12(10):2029-2049 (2017)).
- the number of assay steps it can be desirable to reduce the number of assay steps, for example, reduce the number of hybridization and wash steps.
- One way of reducing the number of assay steps is to pre-assemble some or all components of the SGC prior to contacting with a cell. Such a pre-assembly can be performed by hybridizing some or all of the components of the SGC together prior to contacting the target nucleic acid.
- the invention also provides a sample comprising a cell or a plurality of cells.
- the cell can optionally be fixed.
- the cells can optionally be permeabilized. Fixing and/or permeabilizing cells is particularly applicable to in situ hybridization assays.
- the invention also provides in one embodiment a sample of fixed and
- permeabilized cells comprising (A) at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier, wherein the pre-amplifier is hybridized to the first and second target probes; (D) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe, and wherein the amplifiers are hybridized to the pre-amplifier; and (E) a plurality of label probes, wherein the label probe comprises a
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a sample of fixed and permeabilized cells, comprising (A) at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre-pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre-amplifier comprises a binding site for the second target probe, wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier, and wherein the pre-pre-amplifiers are hybridized to the first and second target probes; (A) at least one fixed and
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both pre-pre-amplifiers is higher than the melting temperature between the binding of only one pre-pre-amplifier.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a sample of fixed and permeabilized cells, comprising (A) at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier, wherein the pre-pre-amplifier is hybridized to the first and second target probes; (D) a plurality of pre-amplifiers comprising a binding site for the pre-pre-amplifiers and a plurality of binding sites for an amplifier, wherein the pre-amplifiers are hybridized to the pre
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA, RNA, or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention additionally provides a slide comprising a cell or a plurality of cells.
- the cell or cells are fixed to the slide.
- the cell or cells are
- the cells on the slide are fixed and/or
- the invention provides a slide comprising (A) a slide having immobilized thereon a plurality of fixed and permeabilized cells comprising at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier, wherein the pre-amplifier is hybridized to the first and second target probes; (D) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe, and wherein the amplifiers are
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA
- RNA or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a slide comprising (A) a slide having immobilized thereon a plurality of fixed and permeabilized cells comprising at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre- pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre- amplifier comprises a binding site for the second target probe, and wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier, and wherein the pre-pre-amplifiers
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both pre-pre-amplifiers is higher than the melting temperature between the binding of only one pre-pre-amplifier.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA
- RNA or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention provides a slide comprising (A) a slide having immobilized thereon a plurality of fixed and permeabilized cells comprising at least one fixed and permeabilized cell containing a target double stranded nucleic acid; (B) a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe specifically hybridized to a first strand of a target double stranded nucleic acid, and a second probe specifically hybridized to the second strand of the double stranded nucleic acid; (C) a pre-pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier, wherein the pre-pre- amplifier is hybridized to the first and second target probes; (D) a plurality of pre-amplifiers comprising a binding site for the pre-pre-amplifier and a plurality of binding sites for an amplifier, wherein
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the double stranded nucleic acid is DNA
- RNA or a DNA/RNA hybrid.
- the sample is a tissue specimen or is derived from a tissue specimen.
- the sample is a blood sample or is derived from a blood sample.
- the sample is a cytological sample or is derived from a cytological sample.
- the invention also provides a kit comprising the components of an SGC, as described herein, where the kit does not include the target nucleic acid.
- a kit can comprise pre-amplifiers (PAs), amplifiers (AMPs) and label probes (LPs), and optionally pre- pre-amplifiers (PPAs), as disclosed herein.
- the kit can comprise target probes (TPs) directed to a particular target double stranded nucleic acid, or a plurality of target double stranded nucleic acids.
- the components of a kit of the invention can optionally be in a container, and optionally instructions for using the kit can be provided.
- the invention provides a kit for detection of a target double stranded nucleic acid, comprising (A) a pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for an amplifier; (B) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe; and (C) a plurality of label probes, wherein the label probe comprises a label and a binding site for the amplifiers.
- the kit comprises a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the kit comprises at least one reagent for permeabilizing cells.
- the invention provides a kit for detection of a target double stranded nucleic acid, comprising (A) a set of pre-pre-amplifiers comprising a first and second pre-pre-amplifier, wherein the first pre-pre-amplifier comprises a binding site for the first target probe, wherein the second pre-pre-amplifier comprises a binding site for the second target probe, and wherein the first and second pre-pre-amplifiers comprise a plurality of binding sites for a pre-amplifier; (B) a plurality of pre-amplifiers, wherein the pre-amplifiers comprise a binding site for the first and second pre-pre-amplifiers and a plurality of binding sites for an amplifier; (C) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifiers and a plurality of binding sites for a label probe; and (D) a plurality of label probes, wherein the label probe comprises a label and a binding
- the kit comprises a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the double stranded nucleic acid.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the pre-amplifier comprises a binding site for the first and second pre-pre-amplifiers, wherein the melting temperature between the binding to both pre-pre-amplifiers is higher than the melting temperature between the binding of only one pre-pre-amplifier.
- the kit comprises at least one reagent for permeabilizing cells.
- the invention provides kit for detection of a target double stranded nucleic acid, comprising (A) a pre-pre-amplifier comprising a binding site for the first target probe, a binding site for the second target probe, and a plurality of binding sites for a pre-amplifier; (B) a pre-amplifier comprising a binding site for the pre-pre-amplifier and a plurality of binding sites for an amplifier; (C) a plurality of amplifiers, wherein the amplifiers comprise a binding site for the pre-amplifier and a plurality of binding sites for a label probe; and (D) a plurality of label probes, wherein the label probe comprises a label and a binding site for the amplifiers.
- the kit comprises a target probe set, wherein the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the target double stranded nucleic acid.
- the target probe set comprises a pair of target probes comprising a first probe that specifically hybridizes to a first strand of a target double stranded nucleic acid, and a second probe that specifically hybridizes to the second strand of the target double stranded nucleic acid.
- the target probe set comprises two or more pairs of target probes that specifically hybridize to the same target nucleic acid.
- the kit comprises at least one reagent for permeabilizing cells.
- This example describes in situ detection of double stranded nucleic acids.
- FIG. 1 A pair of probes were designed for detection of the fibroblast growth factor receptor 1 (FGFR1) gene, essentially as shown in Figure IB.
- FGFR1 fibroblast growth factor receptor 1
- FIG. 1B An overview of the assay protocol is shown in Figure 2 as optimized LS red assay with chemical denaturation ( Figure 2, right panel). The assay was performed essentially according to the manufacturer’s assay conditions for RNAScopeTM 2.5 LS red (Advanced Cell
- HEK293 cells were contacted with sense and antisense probes to detect genomic DNA for FGFR1, tumor protein 53 (TP53, also referred to as p53), and cyclin dependent kinase inhibitor 2A
- CDKN2A CDKN2A
- FGFR1, TP53 and CDKN2A were detected as red punctate dots inside nuclei (blue).
- Tissue samples were also tested for the ability to detect genes in situ.
- Tissue samples of colon cancer, normal pancreas and normal breast were contacted with sense and antisense probes for detection of epidermal growth factor receptor (EGFR) gene and detected by in situ hybridization essentially as described above.
- EGFR epidermal growth factor receptor
- a tissue sample of ovarian cancer was contacted with sense and antisense probes for detection of E3 ubiquitin-protein ligase Mdm2 (MDM2) gene.
- MDM2 E3 ubiquitin-protein ligase Mdm2
- probe pairs for detection of double stranded nucleic acids can be used to detect genes in situ in cell lines and tissue samples.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817449P | 2019-03-12 | 2019-03-12 | |
PCT/US2020/022010 WO2020185846A1 (en) | 2019-03-12 | 2020-03-11 | Detection of double stranded nucleic acids in situ and methods related thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3938535A1 true EP3938535A1 (en) | 2022-01-19 |
EP3938535A4 EP3938535A4 (en) | 2022-12-28 |
Family
ID=72427590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20770887.6A Withdrawn EP3938535A4 (en) | 2019-03-12 | 2020-03-11 | Detection of double stranded nucleic acids in situ and methods related thereto |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220177953A1 (en) |
EP (1) | EP3938535A4 (en) |
JP (1) | JP2022525101A (en) |
CN (1) | CN113795592A (en) |
WO (1) | WO2020185846A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465175B2 (en) * | 1997-09-04 | 2002-10-15 | Bayer Corporation | Oligonucleotide probes bearing quenchable fluorescent labels, and methods of use thereof |
US7709198B2 (en) * | 2005-06-20 | 2010-05-04 | Advanced Cell Diagnostics, Inc. | Multiplex detection of nucleic acids |
US20120052498A1 (en) * | 2010-07-01 | 2012-03-01 | Affymetrix, Inc. | Detection of Nucleic Acids |
US20120003648A1 (en) * | 2010-07-01 | 2012-01-05 | Affymetrix, Inc. | Signal Multiplexing and Signal Amplification |
US20120004132A1 (en) * | 2010-07-02 | 2012-01-05 | Affymetrix, Inc. | Detection of Nucleic Acids and Proteins |
US9273349B2 (en) * | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
US20150232935A1 (en) * | 2014-02-14 | 2015-08-20 | The General Hospital Corporation | Methods for diagnosing igg4-related disease |
EP3913068B1 (en) * | 2015-10-12 | 2023-08-02 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
WO2017168329A1 (en) * | 2016-03-28 | 2017-10-05 | Boreal Genomics, Inc. | Droplet-based linked-fragment sequencing |
-
2020
- 2020-03-11 US US17/438,579 patent/US20220177953A1/en active Pending
- 2020-03-11 CN CN202080033656.7A patent/CN113795592A/en active Pending
- 2020-03-11 EP EP20770887.6A patent/EP3938535A4/en not_active Withdrawn
- 2020-03-11 WO PCT/US2020/022010 patent/WO2020185846A1/en unknown
- 2020-03-11 JP JP2021554678A patent/JP2022525101A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2020185846A1 (en) | 2020-09-17 |
EP3938535A4 (en) | 2022-12-28 |
JP2022525101A (en) | 2022-05-11 |
CN113795592A (en) | 2021-12-14 |
US20220177953A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11535887B2 (en) | Methods for spatial analysis using targeted RNA depletion | |
US20230279477A1 (en) | Methods for spatial analysis using targeted rna capture | |
EP4063519B1 (en) | Methods to further enhance signal amplification for the in situ detection of nucleic acids | |
EP3074539B1 (en) | Method for detecting and characterising a microorganism | |
US20160201117A1 (en) | Ultra sensitive method for in situ detection of nucleic acids | |
JP7531502B2 (en) | Method for multiplexed detection of nucleic acids by in situ hybridization | |
Jackson et al. | A novel loop-mediated isothermal amplification method for identification of four body fluids with smartphone detection | |
US20230002815A1 (en) | Methods for sequential detection of nucleic acids | |
US20150045251A1 (en) | Duplex chromogenic assay for in situ detection of nucleic acids | |
US20220177953A1 (en) | Detection of double stranded nucleic acids in situ and methods related thereto | |
US20220119870A1 (en) | Methods for digital multiplexing of nucleic acids in situ | |
WO2024124041A1 (en) | Multiplexed detection of nucleic acid targets | |
EP4323442A1 (en) | Methods and compositions for reducing autofluorescence | |
EP4147044A1 (en) | Methods for simultaneously detecting target nucleic acids and proteins and a kit thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210804 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221129 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/6876 20180101ALI20221123BHEP Ipc: C12Q 1/6837 20180101ALI20221123BHEP Ipc: C12Q 1/682 20180101AFI20221123BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20230509 |